WASHINGTON, May 4- The U.S. Supreme Court on Monday brought to an end Bristol-Myers Squibb Co's attempt to revive patent protection for its Baraclude treatment for hepatitis B. The high court declined to hear Bristol-Myers' challenge to an appeals court ruling in favor of generic rival Teva Pharmaceutical Industries Ltd, which had successfully challenged the...» Read More
It's my turn. As fate would have it, on the day of Dendreon's first analyst/investor meeting in years, I have to report for jury duty this Thursday in Newark, NJ. But apparently it wouldn't have mattered if I were available anyway or wanted to send a surrogate.
When it rains, it pours. I mean, what a crazy Monday for deals and data in biopharma.
Iin light of evidence that some drug makers have gone to great lengths to turn scientific articles into marketing vehicles for their products, some influential medical editors are cracking down on industry-financed ghostwriting. And they are getting help from some members of Congress.
There! I resisted writing a blog headline that attempts some tired play on words with the Arena Pharmaceuticals' clinical trial acronyms BLOSSOM and BLOOM.
Today is the 16th annual "Newsmakers in Biotech" event put on by Thomson Reuters and BioCentury.
Tomorrow I'll be hanging out at the BioCentury/Thomson Reuters "Newsmakers in the Biotech Industry" conference in NYC, so I won't be able to monitor the webcast of an FDA panel meeting for a most intriguing drug.
Patrick Swayze is sadly a statistic. He is one of an estimated 35,000 people in the United States who will die from pancreatic cancer this year. Several companies are working on drugs for the disease, but the path is littered with failures.
Tips for cultivating marijuana. Testimonials by patients about its medical benefits. Cannabis cooking lessons. Even citations for award-winning strains of pot. Viewers here can now watch, every week, what amounts to a pro-weed news program.
Surely, Eli Lilly didn't throw it's restructuring plan together in a couple of weeks, but it was just the end of last month when Leerink Swann analyst Seamus Fernandez said LLY needed to cut costs and/or do a big deal. So, kudos to him for getting out ahead of it.
Usually when a company announces an executive departure the news comes out in a press release with a header along the lines of , "So-and-so to retire, search begins for successor," or, "XYZ Corp. CEO resigns, interim CEO appointed," etc.
Some analysts had been telling clients recently that they thought Vivus' diet drug Qnexa could take the lead in the three-contestant race to get the next prescription diet pill on the market. But they didn't think it would take such a commanding lead.
Talk about a short tenure. Only eight months after Roche installed him as CEO of Genentech, Pascal Soriot is moving on (up?) to become COO of Roche's Pharma Division.
Lost in the coverage of the Pfizer-Wyeth deal that day, but nonetheless disclosed in the company's simultaneous earnings release back on January 26th of this year, PFE revealed it had taken a $2.3 billion charge for a pending settlement over marketing.
Virtually every large pharmaceutical company seems to have discovered cancer, and a substantial portion of the smaller biotechnology companies are focused on it as well. Together, the companies are pouring billions of dollars into developing cancer drugs.
After a long delay, Eli Lilly finally launched its new bloodthinner Effient just this month. But analysts are already buzzing about what's next.
Reading Betsy McCaughey’s op-ed article in today’s Wall Street Journal, I understand fully why the elderly are so scared about the possibility of a nationalized health care system.
British drugmaker GlaxoSmithKline is trying to keep from having to tighten its belt over new safety concerns with its weightloss pill, alli
Real choice is not part of the bills moving through the Democratic-led Congress; even if the much-debated government-run insurance plan was created, it would not be available to most people who already have coverage.
Am I missing something? Or is this not the way to go about advancing your cause?
A growing body of evidence suggests that doctors at some of the nation’s top medical schools have been attaching their names and lending their reputations to scientific papers that were drafted by ghostwriters working for drug companies - articles that were carefully calibrated to help the manufacturers sell more products.